Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".
Bluechiip Ltd (ASX:BCT) sales and marketing teams both in Australia and the United States continue to make progressive negotiations with potential OEMs especially in the IVF and Cell Therapy markets despite current COVID-19 travel restrictions.
Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m.
Nyrada Inc (ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).
Bluechiip Ltd (ASX:BCT) has a world first, highly differentiated technology, with protected IP and a $200M growing target market, with very large adjacent markets.
